Company & Sponsor Intelligence

Forest Laboratories

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials8

Recruiting0

Completed7

Countries1

Therapeutic footprint

alzheimersautismdepression

Indexed studies

NCT02372799Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)
depression · United StatesPHASE3

NCT01034267Safety Study of F2695 SR in Major Depressive Disorder
depression · United StatesPHASE3

NCT00107120The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
depression · United StatesPHASE3

NCT01592786An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
autism · United StatesPHASE2

NCT00872898Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
autism · United StatesPHASE2

NCT00090116The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
alzheimers · United StatesPHASE3

NCT00644358A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)
depression · United StatesPHASE3

NCT01592773Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
autism · United StatesPHASE2

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →